TP53 and mantle cell lymphoma: Baquero et al. assessed the EZH2 expression in 166 primary MCL, where 57 cases (38%) were positive for EZH2 expression and were associated with aggressive histologic variants (65% vs. 29%), high Ki-67 proliferation rate (72% vs. 19%), and p53 overexpression (43% vs. 2%) compared to EZH2 negative tumors.